The following drug companies made headlines this past week.
1. Bristol-Myers susceptible to acquisition following failed cancer trial, investors say
Bristol-Myers Squibb lost $37 billion in market value this past year due to a failed clinical trial for a new lung cancer treatment indication of its best-selling cancer drug Opdivo. Industry analysts believe the financial setback puts the drugmaker in a vulnerable position for a potential takeover.
2. Lupin Pharma recalls birth control pills over packaging errors
Lupin Pharmaceuticals recalled its Mibelas 24 Fe birth control tablets following confirmed reports of a packaging error.
3. EpiPen scandal grounds for removal of Mylan board members, says advisory firm
Institutional Shareholder Services, a major shareholder advisory firm, is urging Mylan stockholders to vote for the removal of 10 board members, including board Chairman Robert Coury and CEO Heather Bresch.
4. Takeda Pharma taps AI platform for drug development
Takeda Pharmaceuticals will collaborate with Numerate, a computational drug design company, on a new drug development initiative.
5. More than 48k bottles of Bristol-Myers' blood thinner recalled over dosing error
Bristol-Myers Squibb on June 10 recalled more than 48,000 bottles of its blood thinner Eliquis due to dosage issues.
6. Sanofi to invest $673M annually in biologics over next few years
Sanofi will invest $673 million annually in biologic drug development over the next two to three years.
More articles on supply chain:
Medical Design Excellence Awards names top medical devices of 2017
More than 48k bottles of Bristol-Myers' blood thinner recalled over dosing error
Takeda Pharma taps AI platform for drug development